These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30696606)

  • 21. Regulatory T Cells and Tumor-Associated Macrophages in the Tumor Microenvironment in Non-Muscle Invasive Bladder Cancer Treated with Intravesical Bacille Calmette-Guérin: A Long-Term Follow-Up Study of a Japanese Cohort.
    Miyake M; Tatsumi Y; Gotoh D; Ohnishi S; Owari T; Iida K; Ohnishi K; Hori S; Morizawa Y; Itami Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Shimada K; Konishi N; Tanaka N; Fujimoto K
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29048388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment.
    Zeng S; Xing S; Zhang Y; Wang H; Liu Q
    J Zhejiang Univ Sci B; 2024 Jul; 25(7):557-567. PubMed ID: 39011676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
    Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
    Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of lubricants on viability of bacillus Calmette-Guerin for intravesical immunotherapy against bladder carcinoma.
    Böhle A; Rüsch-Gerdes S; Ulmer AJ; Braasch H; Jocham D
    J Urol; 1996 Jun; 155(6):1892-6. PubMed ID: 8618281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Killed but metabolically active Mycobacterium bovis bacillus Calmette-Guérin retains the antitumor ability of live bacillus Calmette-Guérin.
    Secanella-Fandos S; Noguera-Ortega E; Olivares F; Luquin M; Julián E
    J Urol; 2014 May; 191(5):1422-8. PubMed ID: 24333111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
    Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
    Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: Bacillus Calmette-Guérin (BCG) Therapy Lowers the Incidence of Alzheimer's Disease in Bladder Cancer Patients.
    Chang SS
    J Urol; 2020 Dec; 204(6):1379. PubMed ID: 32956002
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis.
    Boehm BE; Cornell JE; Wang H; Mukherjee N; Oppenheimer JS; Svatek RS
    J Urol; 2017 Sep; 198(3):503-510. PubMed ID: 28286068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mediastinal mass mimicking a tumor in a patient with bladder cancer after Bacillus Calmette-Guerin treatment.
    Somoskovi A; Carlyn C; Dormandy J; Salfinger M
    Eur J Clin Microbiol Infect Dis; 2007 Dec; 26(12):937-40. PubMed ID: 17899227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway.
    Mao MH; Huang HB; Zhang XL; Li K; Liu YL; Wang P
    Biomed Pharmacother; 2018 Nov; 107():1093-1103. PubMed ID: 30257321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer.
    Steinberg RL; Nepple KG; Velaer KN; Thomas LJ; O'Donnell MA
    Urol Oncol; 2017 Dec; 35(12):670.e7-670.e14. PubMed ID: 28801026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
    Gandhi NM; Morales A; Lamm DL
    BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V; Pode D; Pikarsky E; Mandelboim O
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.
    Kamat AM; Briggman J; Urbauer DL; Svatek R; Nogueras González GM; Anderson R; Grossman HB; Prat F; Dinney CP
    Eur Urol; 2016 Feb; 69(2):197-200. PubMed ID: 26119560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pulmonal bacillus Calmette-Guérin infection two years after intravesical bacillus Calmette-Guérin installation].
    Harbjerg JL; Bjerre CC; Lillebæk T; Weinreich UM
    Ugeskr Laeger; 2014 Dec; 176(25A):. PubMed ID: 25497624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
    Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
    Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study.
    Pfister C; Kerkeni W; Rigaud J; Le Gal S; Saint F; Colombel M; Guy L; Wallerand H; Irani J; Soulie M;
    Int J Urol; 2015 Jan; 22(1):53-60. PubMed ID: 25256813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
    Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
    Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.